Jazz Pharmaceuticals Plc - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on April 15, 2011, by Jazz Pharmaceuticals, Inc. (now Jazz Pharmaceuticals Plc). The filing addresses the entry into a new Master Services Agreement and the termination of a prior agreement regarding the distribution of the Company's product, Xyrem, in the United States.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on contractual agreements rather than financial performance data.
Material Changes
- New Agreement: On April 15, 2011, the Company entered into a Master Services Agreement with CuraScript, Inc. and its affiliate, Express Scripts Specialty Distribution Services, Inc.
- Scope: The agreement grants exclusive distribution and customer support services for the sale and marketing of Xyrem in the United States.
- Termination: The execution of the new agreement terminated the Prior Master Services Agreement dated May 6, 2008.
- Terms: The Company is billed monthly for services. The agreement expires on June 30, 2015, with automatic two-year extensions unless terminated with 120 days' notice.
- Continuity: The Company states there are no material changes to the rights and obligations of the parties between the new and prior agreements.
Outlook, Risks, and Management Commentary
Management commentary is limited to the description of the agreement terms. The filing notes that the full text of the Master Services Agreement will be filed as an exhibit to the Form 10-Q for the quarter ended March 31, 2011. No specific risks, contingencies, or unusual items are detailed in this report beyond the standard contractual obligations.
Key Facts for Investor Verification
- Verify the full text of the Master Services Agreement in the upcoming Form 10-Q for the quarter ended March 31, 2011.
- Confirm that the transition from the 2008 agreement to the 2011 agreement resulted in no disruption to Xyrem distribution.
- Monitor future filings for any amendments to the automatic extension terms or termination notices.